Cleo Diagnostics Advances Ovarian Cancer Test Development

CLEO Diagnostics Ltd ( (AU:COV) ) has shared an announcement.

Cleo Diagnostics Ltd has reached a significant milestone in the development of its ovarian cancer diagnostic test by commencing technology transfer activities. This step involves collaboration with R&D Systems, Inc. to scale up production and prepare for large-scale manufacturing. The achievement is pivotal for Cleo’s strategic pathway towards FDA submission and commercial production, aiming to address the global unmet need for early ovarian cancer detection. Successful technology transfer is expected to enhance Cleo’s market positioning and operational capabilities, with final negotiations underway with FDA-approved CMOs to ensure compliance and scalability.

More about CLEO Diagnostics Ltd

Cleo Diagnostics Ltd is a company focused on developing a simple blood test for the early and accurate diagnosis of ovarian cancer. The test is based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. Cleo Diagnostics holds a worldwide exclusive license to commercialize this technology, which is backed by over 10 years of research and development at the Hudson Institute of Medical Research.

YTD Price Performance: 22.54%

Average Trading Volume: 142,807

Technical Sentiment Consensus Rating: Strong Sell

See more insights into COV stock on TipRanks’ Stock Analysis page.